Bottom line
Is ASGTX a good fund? The bottom line
ASGTX is a share class of Transamerica Small Cap Growth, a managed small-cap mutual fund from Transamerica.
Its expense ratio is 1.4% — about $140 a year on every $10,000 invested, more expensive than 82% of small-cap funds we track.
It returned −8.6% over one year, −1.3% a year over five years, +7.3% a year over ten (as of Dec 31, 2025, per its prospectus).
With $80.8 million in net assets and 58 holdings, its largest position is Ligand Pharmaceuticals Inc (4.5%) and the top 10 make up 29.8% of the portfolio.
This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.4%)
- 5-year return in the bottom quarter of its category
- Front-end sales load up to 5.5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What ASGTX invests in
Seeks long-term capital appreciation.
Under normal circumstances, the fund invests at least 80% of its net assets (plus the amount of borrowing, if any, for investment purposes) in stocks of small capitalization companies. The funds sub-adviser, Ranger Investment Management, L.P. (the sub-adviser), primarily focuses on seeking to identify high quality, high-growth small capitalization companies. The sub-adviser considers small capitalization companies to be companies with market capitalizations which, at the initial time of purchase, are within the capitalization range of issuers represented within the Russell 2000 Growth Index 1 , a benchmark of the fund, which as of June 27, 2025, the most recent reconstitution date of the index, was between $119.4 million and $7.4 billion. The sub-advisers approach to security selection seeks quality growth companies by implementing a bottom-up, fundamental research driven security…
From the fund's prospectus (filed Feb 27, 2026).
ASGTX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| ASGTX | −8.6% | −1.3% | +7.3% |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What ASGTX costs
On a $10,000 investment, ASGTX's 1.4% expense ratio costs about $140 a year. The prospectus estimates $2,272 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
ASGTX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Ligand Pharmaceuticals Inc | 4.49% |
| 2 | SharkNinja Inc | 3.33% |
| 3 | UL Solutions Inc | 3.27% |
| 4 | Oceaneering International Inc | 3.11% |
| 5 | Chime Financial Inc | 2.84% |
| 6 | HealthEquity Inc | 2.74% |
| 7 | PDF Solutions Inc | 2.66% |
| 8 | Triumph Financial Inc | 2.46% |
| 9 | Casella Waste Systems Inc | 2.45% |
| 10 | Excelerate Energy Inc | 2.44% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 29.8% of the fund. See all top 25 holdings and asset mix →